•  In January 2010 the company reached a settlement with the holders of a secured promissory note that had been in default.

  •   Due to the company being unable to come to a settlement agreement with a large creditor, on August 10, 2009 it filed for protection under Chapter 11 of the US Bankruptcy code.  The case was dismissed in November 2009. 

  •   Clinical effect of nemifitide, a novel pentapeptide antidepressant, in the treatment of severely depressed refractory patients, published in January 2008 issue of International Clinical Psychopharmacology

  • View the June 2007 Chairman's letter to the shareholders.

  • On June 14, 2007 the NASD approved Tetragenex Pharmaceuticals, Inc. to be quoted on the NASDAQ Bulletin Board under the symbol TTRX.

  • Tetragenex files an SB-2 with the SEC with the goal of registering all of its common shares and shares underlying all warrants/options.

  • On November 26, 2004 as part of the reorganization agreement, Innapharma emerged from bankruptcy and merged into its wholly-owned subsidiary Tetragenex Pharmaceuticals. 

    •   

  • Tetragenex Pharmaceuticals Inc. Presents at Pasteur Institute European Conference

  • KBC and its affiliates invested USD 5 million in Tetragenex Pharmaceuticals Inc. in 2002.

  • Quintiles and Tetragenex Pharmaceuticals Inc.(Innapharma) Announce Preferred Provider Agreement for Studies of Central Nervous System Disorders

    •